These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1845121)

  • 21. Will there be a live-attenuated HIV vaccine available for human safety trials by the year 2000? Interview by Gordon Nary.
    Desrosiers RC
    J Int Assoc Physicians AIDS Care; 1998 Nov; 4(11):22-3. PubMed ID: 11366120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The status of HIV/AIDS vaccines--1993.
    Weber J
    Ther Immunol; 1994 Apr; 1(2):95-100. PubMed ID: 7584488
    [No Abstract]   [Full Text] [Related]  

  • 24. Mucosal transmission of virulent and avirulent lentiviruses in macaques.
    Pauza CD; Horejsh D; Wallace M
    AIDS Res Hum Retroviruses; 1998 Apr; 14 Suppl 1():S83-7. PubMed ID: 9581890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV vaccination dilemma.
    Sabin AB
    Nature; 1993 Mar; 362(6417):212. PubMed ID: 8318105
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.
    Haynes BF; Yasutomi Y; Torres JV; Gardner MB; Langlios AJ; Bolognesi DP; Matthews TJ; Scearce RM; Jones DM; Moody MA
    Trans Assoc Am Physicians; 1993; 106():33-41. PubMed ID: 8036743
    [No Abstract]   [Full Text] [Related]  

  • 28. Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine.
    Yamamoto JK; Pu R; Sato E; Hohdatsu T
    AIDS; 2007 Mar; 21(5):547-63. PubMed ID: 17314517
    [No Abstract]   [Full Text] [Related]  

  • 29. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model.
    Nehete PN; Nehete BP; Manuri P; Hill L; Palmer JL; Sastry KJ
    Vaccine; 2005 Mar; 23(17-18):2154-9. PubMed ID: 15755586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress and obstacles in the development of an AIDS vaccine.
    Letvin NL
    Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for an HIV vaccine.
    Letvin NL
    J Clin Invest; 2002 Jul; 110(1):15-20. PubMed ID: 12093882
    [No Abstract]   [Full Text] [Related]  

  • 34. Mighty mice. Scientists are still improving the humanized mouse model but are optimistic about its future role in evaluating AIDS vaccine candidates.
    von Bubnoff A
    IAVI Rep; 2008; 12(5):1, 8-11. PubMed ID: 20213868
    [No Abstract]   [Full Text] [Related]  

  • 35. Progress in vaccine development against SIV and HIV.
    Bolognesi DP
    J Acquir Immune Defic Syndr (1988); 1990; 3(4):390-4. PubMed ID: 1690288
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of nonhuman primate models in AIDS vaccine development.
    Johnston MI
    Mol Med Today; 2000 Jul; 6(7):267-70. PubMed ID: 10859562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV research may be right on target for potential vaccine.
    Rees J
    Expert Rev Vaccines; 2013 Jul; 12(7):719. PubMed ID: 23885816
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV vaccine research may be boosted by development of new mouse model with human immune system.
    Constable L
    Expert Rev Vaccines; 2012 Sep; 11(9):1036. PubMed ID: 23297426
    [No Abstract]   [Full Text] [Related]  

  • 39. International Conference on Advances in AIDS Vaccine Development.
    Snow W
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1433-4. PubMed ID: 1466975
    [No Abstract]   [Full Text] [Related]  

  • 40. AIDS vaccine development: let a thousand flowers bloom.
    Oxford JS; Addawe M; Lambkin R
    J Clin Pathol; 1998 Oct; 51(10):725-30. PubMed ID: 10023333
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.